 Patent Application Title |
Patent App Num. |
Date |
| Liposomes for drug delivery and methods for preparation thereof | 20120009243 | 20120112 |
| The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
... |
| Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample | 20110312006 | 20111222 |
| The invention relates to a new method for measuring a calcium-dependent phospholipase A1 or A2 enzymatic activity in a sample, comprising the following steps: a) contacting said sample with a solid phase coated with a fluorochrome-labelled phospholipase A1 or A2 substrate, wherein the molecular coverage is in the range 8 to 30 fluorochrome-labelled phospholipase A1 or A2 substrate molecules/nm2 in conditions where calcium-dependent phospholipase A1 or A2 enzymatic activity is blocked. b) reading the fluorescence emission overtime c) adding a solution to initiate calcium-dependent phospholipase A1 or A2 enzymatic activity d) reading the fluorescence emission overtime, and kits for carrying out said method.
... |
| Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample | 20110312008 | 20111222 |
| The invention relates to a new method for measuring phospholipase A1 or A2 activity in a sample, using a solid phase coated with a fluorochrome-labelled phospholipase A1 or A2 substrate, wherein the molecular coverage is in the range from 8 to 30 fluorochrome-labelled phospholipase A1 or A2 substrate molecules/nm2, and kit for carrying out said method.
... |
| Pyrimidinone inhibitors of lipoprotein-associated phospholipase a2 | 20110306552 | 20111215 |
| The present invention relates to new pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof
... |
| Disease control with tick phospholipase a2 | 20110293596 | 20111201 |
| The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from A. americanum saliva effective in reducing the viability of gram positive, gram negative, or acid-fast bacteria and spirochetes including B. burgdurferi is administered. The inventive protein from A. americanum saliva has utility as a therapeutic for the treatment of an organism infected with bacteria, particularly the spirochete B. burgdorferi.
... |
Subscribe to updates on this page: Phospholipase RSS  |
| Phospholipase c enzyme | 20110293786 | 20111201 |
| A phospholipase C enzyme having the ability to hydrolyze a phospholipid in both acidic and around neutral ranges and in a citrate buffer solution, as well as having a degree of heat stability, and having a property not to hydrolyze phosphate esters not containing lipid moieties. The phospholipase C enzyme shows activity from acidic to neutral pH and does not substantially hydrolyze any phosphate esters except for phospholipids.
... |
| Cloning, expression and use of acid phospholipases | 20110287141 | 20111124 |
| The invention relates to a DNA sequence that encodes a polypeptide with phospholipase activity and was isolated from Aspergillus and sequences derived therefrom, polypeptides with phospholipase activity encoded by these sequences as well as the use of these polypeptides for degumming of vegetable oil, for the preparation of dough and/or bakery products, for the preparation of dairy products, for processing steps in the textile industry and for related applications.
... |
| Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies | 20110269786 | 20111103 |
| Administration of sPLA2 inhibitors in combination with statins has been found to reduce the occurrence of major adverse cardiac events (MACEs), specifically unstable angina (UA) requiring urgent hospitalization, in diabetic subjects who have recently experienced an index ACS event to a significantly greater degree than statins alone. These results were unexpected given previous results showing that statins alone are insufficient to satisfactorily reduce MACEs and inflammation in this high-risk population, combined with the high levels of baseline inflammation associated with diabetes. Therefore, provided herein are methods of treating MACEs, including UA requiring urgent hospitalization, in a diabetic subject who has previously experienced an ACS event by administering one or more sPLA2 inhibitors alone or in combination with one or more statins.
... |
| Compositions and methods for predicting cardiovascular events | 20110269150 | 20111103 |
| The present invention provides compositions, devices, kits, and methods for determining the risk of peri-operative cardiovascular events or predicting cardiovascular events associated with angioplasty. In certain embodiments, the present invention provides methods, compositions, kits, and devices configured for determining the value of at least two markers selected from myeloperoxidase (MPO), an F2-isoprostane (F2-IsoP), C-reactive protein (CRP), urinary micro-albumin (UMA), and lipoprotein-associated phospholipase A2 (Lp-PLAZ), such that a subject's risk of experiencing a cardiovascular event is determined.
... |
| Omega-3 fatty acids for reduction of lp-pla2 levels | 20110251275 | 20111013 |
| Methods are provided for utilizing omega-3 fatty acids, or a combination of a dyslipidemic agent and omega-3 fatty acids, for the reduction of lipoprotein-associated phospholipase A2 (Lp-PLA2) levels. The methods are especially useful in the treatment of patients with primary hypercholesterolemia or hypertriglyceridemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of major adverse cardiovascular events (MACE), major coronary events (MCE), particularly myocardial infarction (MI), revascularizations and ischemic stroke.
... |
| Modified photosynthetic microorganisms for producing lipids | 20110250659 | 20111013 |
| This disclosure describes genetically modified photosynthetic microorganisms, e.g., Cyanobacteria, that contain one or more exogenous genes encoding a phospholipase and/or thioesterase, which are capable of producing an increased amount of lipids and/or fatty acids. This disclosure also describes genetically modified photosynthetic microorganisms that contain one or more exogenous genes encoding a diacyglycerol acyltransferase, a phosphatidate phosphatase, and/or an acetyl-CoA carboxylase, which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides, as well as photosynthetic microorganism comprising mutations or deletions in a glycogen biosynthesis or storage pathway, which accumulate a reduced amount of glycogen under reduced nitrogen conditions as compared to a wild type photosynthetic microorganism.
... |
| Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies | 20110207710 | 20110825 |
| Administration of sPLA2 inhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of sPLA2 inhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore, provided herein are methods of treating dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome, by administering one or more sPLA2 inhibitors. Significantly, administration of sPLA2 inhibitors and various compounds used in the treatment of CVD, such as for example statins, resulted in greater decreases in LDL and LDL particle levels in a synergistic manner. In addition, administration of sPLA2 inhibitors and statins resulted in a synergistic decrease in plaque content. Therefore,... |
| Modifications of solid 3-sn-phosphoglycerides | 20110190238 | 20110804 |
| Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.
... |
Subscribe to updates on this page: Phospholipase RSS |
| Method for screening of substance effective on disease using gpr120 and phospholipase | 20110183318 | 20110728 |
| The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.
... |
| Clinical benefits of eicosapentaenoic acid in humans | 20110178105 | 20110721 |
| Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A2 [“Lp-PLA2”] levels, stabilizing rupture prone-atherosclerotic lesions, decreasing the Inflammatory Index and increasing Total Omega-3 Score™ in humans, by administering an effective amount of eicosapentaecnoic acid [“EPA”], an omega-3 polyunsaturated fatty acid [“PUFA”].
... |
| Diagnostics for membranous nephropathy | 20110177534 | 20110721 |
| The invention relates to immunoassays, reagents, therapeutics and methods of diagnosing and prognosis evaluation of idiopathic membranous nephropathy (MN). Immunoassays comprise enzyme-linked immunoabsorbent assays and nephelometric immunoassays for serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R). Therapeutic methods include removal of the auto-antibodies by absorbance or administration of soluble PLA2R or fragments to sequester the auto-antibodies.
... |
| Lipolytic enzymes | 20110165655 | 20110707 |
| The inventors have developed a method using protein engineering to produce lipolytic enzymes having a relatively high activity for one ester bond in an amphiphilic substrate with two lipophilic groups) and a relatively low activity for the ester bond in an amphiphilic substrate with one lipophilic group, e.g. a relatively high phospholipase activity and a relatively low lysophospholipase activity.
... |
| Vivo detection of phospholipase activation | 20110165084 | 20110707 |
| The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon.
... |
| Process for the preparation of a phospholipase | 20110151540 | 20110623 |
| A process for preparing a phospholipase D of vegetable or nut origin comprises: (i) providing a liquid extract of vegetable or nut origin; (ii) combining the liquid extract with a precipitating agent comprising at least one surfactant optionally in admixture with phospholipids, mono-, di- or triglycerides or a mixture thereof, to produce a suspension comprising a supernatant and a precipitate; and (iii) separating and collecting the precipitate from the suspension produced in (ii).
... |
| Process for producing a phospholipid | 20110143404 | 20110616 |
| A process for preparing phosphatidylserine comprises reacting a phospholipid with serine in the presence of water, a phospholipase D from carrot and at least one surfactant. A process for preparing phosphatide acid comprises hydrolysing a phospholipid in the presence of water and a phospholipase D from carrot.
... |
| Meat based food product | 20110142992 | 20110616 |
| The present invention is related to a method for producing a meat based food product by treating meat with a phospholipase, to a meat based food product obtainable by the method of the invention and to use of a phospholipase for producing a meat based food product.
... |
| Quinolone inhibitors of lipoprotein-associated phospholipase a2 | 20110136861 | 20110609 |
| The present invention relates to new quinolone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof.
... |
| Process | 20110136187 | 20110609 |
| A process of water degumming an edible oil (preferably a crude edible oil) comprising the steps of: a) admixing approximately 0.1-5% w/w water with an edible oil (preferably a crude edible oil) and a lipid acyltransferase, b) agitating the admixture for between about 10 minutes and 180 minutes at about 45 to about 900 C, and c) separating the oil phase and the gum phase. Preferably said lipid acyltransferase is a polypeptide having lipid acyltransferase activity which polypeptide is obtained by expression of the nucleotide sequence shown as SEQ ID No. 49 or a nucleotide sequence which as has 70% or more identity therewith; and/or is obtained by expression of a nucleic acid which hybridises under medium stringency conditions to a nucleic probe comprising the nucleotide... |
| Culture medium enabling staphylococcus aureus to be differentiated from coagulase-negative staphylococci | 20110129871 | 20110602 |
| A specific culture medium for growth, detection, identification and/or counting of Staphylococcus aureus bacteria, said medium includes at least one fluorogenic, chromogenic or luminescent substrate of phospholipase C. Said medium permits differentiation between Staphylococcus aureus and coagulase-negative staphylococci.
... |
| Method for preparation of polyunsaturated fatty acid-containing phosphatidylserine | 20110124061 | 20110526 |
| A method for the preparation of the polyunsaturated fatty acids-containing phosphatidylserine, the method comprising: combining L-serine with a fish liver phosphatidylcholine having a polyunsaturated fatty acid to form a mixture; reacting the mixture with phospholipase D to effect transphosphatidylation of L-serine and the phosphatidylcholine having polyunsaturated fatty acids to produce the polyunsaturated fatty acids-containing phosphatidylserine.
... |
| Amides as inhibitors of human secreted phospholipase a2 | 20110111478 | 20110512 |
| Methods and compounds useful for inhibiting a phospholipase A2 are provided, the methods comprising contacting the phospholipase A2 with a compound having the structure A, or pharmaceutically acceptable salts thereof: wherein R1 is H, F, NH2, or COOH; R2 is, H, linear saturated or unsaturated alkyl, alkenyl, or alkynyl; each of R3 and R4 is independently H, linear saturated or unsaturated alkyl, alkenyl, alkynyl, phenyl, or substituted phenyl; R5 is H, (C1-C6) alkyl such as methyl or ethyl; X is aryl or substituted aryl, such as phenyl or a substituted phenyl; and Y is O or S.
... |
| Process for the production of n-acyl-phosphatidyl-ethanolamine | 20110111469 | 20110512 |
| The document describes a process for the preparation of N-Acyl-Phosphatidyl-Ethanolamine of formula (I) on an industrial scale, In which R1, R2 and R3 are, independently from each other, saturated, monounsaturated or polyunsaturated acyls C10-C30, pure or mixed together, and X=OH or OM, where M=alkaline metal or alkaline earth, ammonium or alkylammonium. The process in question allows the conversion of lecithin of synthetic or natural origin into N-Acyl-Phosphatidyl-Ethanolamine of formula (I) of high purity, using a limited molar excess of the reagent N-acyl-ethanolamine, where the acyl is as defined above for the formula (I) through reaction of transphosphatidylation in the presence of the enzyme phospholipase D and in conditions suitable for production on an industrial scale.
... |
| Formulations of px compounds | 20110097410 | 20110428 |
| Nanoparticles of PX compounds in the size range of 10 to 1000 nanometers are incorporated into formulations that are safe for intravenous administration and used to treat disease conditions caused by phospholipase A2 (PLA2) such as ischemia-reperfusion injury.
... |
| Phospholipases, nucleic acids encoding them and methods for making and using them | 20110093965 | 20110421 |
| The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.
... |
| Uses of lp-pla2 in combination to assess coronary risk | 20110070223 | 20110324 |
| This invention relates to a method for assessing risk of Coronary Vascular Disease (CVD). Specifically, it relates to utilizing risk assessment from both Lipoprotein Associated Phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) in combination. In addition the invention relates to a method for assessing risk of Coronary Vascular Disease (CVD) in a patient with low to normal Low Density Lipoprotein Cholesterol (LDL) levels utilizing both LDL and Lipoprotein Associated Phospholipase A2 (Lp-PLA2). Moreover, the invention relates to the use of risk associated with Lp-PLA2, CRP and LDL in combination and specific ranges thereof to predict Coronary Vascular Disease.
... |
| Composition and method for promoting survival of aged basal forebrain cholinergic neuron leading to provention and treatment of age-related neurodegenerative disorder | 20110003775 | 20110106 |
| A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine. A composition for treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, the composition comprising: a lipid composition comprising: a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and... |
| Process to remove impurities from triacylglycerol oil | 20110003370 | 20110106 |
| The present invention is directed to a process to remove impurities from triacylglycerol oil including mixing the oil and a fluidic agent, pumping the mixture through a flow-through hydrodynamic cavitation apparatus at a pre-determined inlet pump pressure, creating hydrodynamic cavitation in the mixture, maintaining the hydrodynamic cavitation for a pre-determined period of time, moving the impurities from the oil to the fluidic agent, and then separating the fluidic agent from the oil. The impurities can include phytosterols, sterol glucosides, acylated sterol glucosides, in which case the fluidic agent is water, an alkali hydroxide, an inorganic base, an organic base, phosphoric acid, citric acid, acetic acid or a mixture thereof. The impurities may also include phosphatides, in which case and the fluidic agent comprises water and an... |
| Modulation of the phospholipase a2 pathway as a therapeutic | 20100331280 | 20101230 |
| There is provided a method of modifying vasoactivity by regulating a soluble Aβ pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble Aβ pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble Aβ pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble Aβ pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.
... |
| Diacyl indazole derivatives as lipase and phospholipase inhibitors | 20100286133 | 20101111 |
| Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds as pharmaceutical products.
... |
| Phospholipase c and method of use | 20100284992 | 20101111 |
| The present invention provides a method for reducing angiogenesis using a phospholipase C.
... |
| System and method for evaluating blood-neural barrier permeability | 20100273196 | 20101028 |
| A system and method for evaluating blood-neural barrier permeability. Phospholipid liposomes are labeled with a fluorescent phospholipase A2 substrate and exposed to cerebrospinal fluid. The change in fluorescence is monitored to determine PLA2 activity. The PLA2 activity is used to evaluate the permeability and function of the blood-neural barrier.
... |
| Compounds and methods of use thereof for assaying lysophospholipase d activity | 20100260682 | 20101014 |
| Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening (HTS) for identification of potential inhibitors of lysoPLD activity.
... |
| Method and kit for quantitatively determining small, dense ldl cholesterol | 20100255516 | 20101007 |
| (2) quantitatively determining cholesterol in lipoproteins remaining in step (1) above.
... |
| Enzymatic oil recuperation process | 20100240917 | 20100923 |
| A process for the recuperation of acylglycerols or acylglycerols containing free fatty acids from gums, present as aqueous emulsions, said gums being obtained by subjecting triglyceride oil to one or more degumming processes, said recuperation process comprising the steps of: subjecting said gums to enzymatic hydrolysis catalysed by one or more enzymes with phospholipase activity; allowing said gums to separate into two or more phases, said two or more phases including at least an oily phase and an aqueous phase; and recuperating said oily phase comprising acylglycerols or acylglycerols containing free fatty acids; wherein said enzymatic hydrolysis is accelerated by adding at least part of the one or more enzymes with phospholipase activity to at least part of the water used in the recuperation and/or at... |
| Novel heteroaryl-substituted acetone derivative, suitable for inhibiting phospholipase a2 | 20100240718 | 20100923 |
| The present invention relates to novel heteroaryl-substituted acetone derivatives inhibiting the enzyme phospholipase A2, and pharmaceutical agents comprising said compounds.
... |
| Biochemical test for confirming the presence of l. monocytogenes | 20100240091 | 20100923 |
| The invention relates to a biochemical test for confirming the presence of L. monocytogenes, characterized in that it comprises at least one phosphatidylinositol phospholipase C (PI-PLC) substrate and at least one alpha-mannosidase substrate.
... |
| Genetic markers for predicting disease and treatment outcome | 20100233719 | 20100916 |
| The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy.
... |
| Method of screening substance useful in treating disease with the use of gpr40 and phospholipase | 20100227350 | 20100909 |
| The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.
... |
| Enzyme-assisted de-emulsification of aqueous lipid extracts | 20100227042 | 20100909 |
| Compositions and processes for destabilizing an oil-in-water emulsion resulting from the aqueous solvent extraction of plant oils are disclosed. The processes comprise the use of one or more enzyme activities including phospholipase and protease activity. The processes are useful for improving the extraction of oil from oilseeds, as well as for obtaining more desirable proteins from those oilseeds.
... |
| Biosensors to measure insp3 concentration in living cells | 20100210819 | 20100819 |
| Phosphoinositides participate in many signaling cascades via phospholipase C stimulation, which hydrolyzes phosphatidylinositol bisphosphate, producing second messengers diacylglycerol and inositol 1,4,5-trisphosphate (InsP3). Destructive chemical approaches required to measure [InsP3] limit spatio-temporal understanding of subcellular InsP3 signaling. Disclosed are new biosensors and test kits which allow studying InsP3 dynamics at high temporal and spatial resolution, thereby understanding InsP3 signaling in intact cells.
... |
| Modified-immobilized enzymes of high tolerance to hydrophilic substrates in organic media | 20100209982 | 20100819 |
| Disclosed are preparations of modified interfacial enzymes, particularly lipases and phospholipases, immobilized on a solid support, wherein the enzyme is surrounded by hydrophobic microenvironment, thereby protected from deactivation and/or aggregation in the presence of hydrophilic agents, substrates and/or reaction products. The enzyme may be protected by being covalently bonded with lipid groups which coat the enzyme, or by being immobilized or embedded in a hydrophobic solid support. Also disclosed are processes for the preparation of the hydrophobically protected enzymes. The enzymes may be efficiently used in the preparation of biodiesel.
... |
| Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | 20100204249 | 20100812 |
| Niacin drugs are frequently utilized as a therapeutic to treat CVD, increase HDL levels, and/or decrease TG levels. As disclosed herein, it has been found that administration of one or more sPLA2 inhibitors in combination with one or more niacin drugs unexpectedly results in a synergistic increase in HDL levels and a synergistic decrease in TG levels. Therefore, compositions, methods, and kits are provided for treating CVD, increasing HDL levels, decreasing TG levels, and improving HDL/LDL ratios.
... |
| 2-substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | 20100204223 | 20100812 |
| The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved.
... |
| Fluorescent phospholipase a2 indicators | 20100203564 | 20100812 |
| Compositions, methods of synthesis and applications of phospholipase A2 (PLA2) specific enzyme substrates which exhibit fluorescence resonance energy transfer (FRET) are described. The compounds generally have the structure: (I) wherein, the variables are described throughout the application. These novel compounds provide a sensitive method to monitor real time PLA2 specific enzyme activities in various cells, tissues and small organisms with fluorescence-ratiometric analysis.
... |
| Triazolopyridine derivatives as inhibitors of lipases and phospholipases | 20100190801 | 20100729 |
| The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.
... |
| Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase d and raptor | 20100184636 | 20100722 |
| The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.
... |
| Human phospholipase a2 epsilon | 20100183626 | 20100722 |
| A novel function phospholipase A2, referred to herein as calcium-independent phospholipase A2ε (iPLA2ε) having SEQ ID NO: 1 and SEQ ID NO: 2, and nucleic acid sequences (SEQ ID NO: 3 and SEQ ID NO: 4) encoding and expressing iPLA2ε is disclosed. This novel enzyme has been isolated and characterized and is involved in the catalysis and hydrolysis of lipids cycling in a living cell biosystem. In an embodiment, the iPLA2ε polypeptide is encoded and expressed by an isolated nucleic acid molecule comprising a set of iPLA2ε polynucleotides. In one aspect, an isolated and characterized gene comprises a polynucleotide having a sequence shown in SEQ ID NO: 3 and SEQ ID NO: 4.
... |
| Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors | 20100173961 | 20100708 |
| The invention relates to benzooxazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.
... |
| Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies | 20100160361 | 20100624 |
| Administration of sPLA2 inhibitors in combination with statins has been found to reduce major adverse cardiac events (MACEs), inflammatory biomarker levels, and LDL-C levels in subjects who have recently experienced an index ACS event to a significantly greater degree than statins alone. These results were unexpected given previous results showing that statins alone are insufficient to satisfactorily reduce MACEs and inflammation in this high-risk population. Therefore, provided herein are methods of treating MACEs, treating ACS, inhibiting inflammation, and lowering cholesterol levels in a subject who has previously experienced an ACS event by administering one or more sPLA2 inhibitors alone or in combination with one or more statins.
... |
| Method of treating foodstuff | 20100159093 | 20100624 |
| The present invention relates to a method of improving the safety, the quality and the durability of foodstuffs and raw materials which are used in the production of foodstuffs, and to a foodstuff or a foodstuff raw material. A foodstuff or a foodstuff raw material is treated with pure nitrogen gas in order to prevent the growth of microbes in the foodstuff or the foodstuff raw material. The nitrogen gas method according to the present invention makes it possible to eliminate efficiently the bacteria which produce large quantities of phospholipase from the foodstuff or the foodstuff raw material. The nitrogen gas method is especially suitable for the treatment of milk products, particularly raw milk.
... |
| 5-oxoisoxazoles as inhibitors of lipases and phospholipases | 20100152246 | 20100617 |
| The present invention relates to 5-oxoisoxazole derivatives of the formula I, the pharmaceutically usable salts thereof and the use thereof as medicinal substances.
... |
| Assay methods for identifying agents that modify the activity of nape-pld or abh4 | 20100143937 | 20100610 |
| The present invention provides methods for the detection of agents that modify the activity of the N-acylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD) enzyme or the Alpha/beta-hydrolase-4 (Abh4) enzyme. The disclosed methods are configured in an assay format amenable to high throughput screening applications.
... |
| Anti-inflammatory agent | 20100120903 | 20100513 |
| An anti-inflammatory agent which includes an oil-soluble licorice extract, prepared by subjecting at least one of a leguminous plant of the genus Glycyrrhiza and a water extraction residue of a leguminous plant of the genus Glycyrrhiza to an extraction treatment with an organic solvent and which has at least one effect selected from an inhibitory effect on hyaluronidase activity, an inhibitory effect on hexosaminidase release (i.e., inhibitory effect on histamine release), an inhibitory effect on platelet aggregation, and an inhibitory effect on phospholipase A2 activity.
... |
| Cloning, expression and use of acid lysophospholipases | 20100119656 | 20100513 |
| The invention relates to a DNA sequence that encodes a polypeptide with lysophospholipase activity and was isolated from Aspergillus and sequences derived therefrom, polypeptides with lysophospholipase activity encoded by these sequences as well as the use of these polypeptides for improving the filterability of syrups consisting of wheat starch and for related applications.
... |
| Liquid formulations of phospholipase enzyme inhibitors | 20100113443 | 20100506 |
| The present invention relates to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof.
... |
| Reagens for the detection of protein acetylation signaling pathways | 20090325312 | 20091231 |
| The invention discloses 426 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites/proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Methyltransferases, Transcription factors, Transcription coactivators, Translation initiation complex proteins, Oxireductases, Protein kinases, RNA binding proteins, Secreted proteins, Transferases, Transporter proteins, Ubiquitin conjugating system proteins, Motor proteins, Phosphotases, Proteases, Phospholipases, Receptor proteins and Vesicle proteins.
... |
| Use of spla2 activity for the diagnosis of a cardiovascular event | 20090325194 | 20091231 |
| A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.
... |
| Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis | 20090324575 | 20091231 |
| The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
... |
| Esterases and related nucleic acids and methods | 20090324574 | 20091231 |
| The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phosphplipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis... |
| Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors | 20090318492 | 20091224 |
| Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.
... |
| Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors | 20090306171 | 20091210 |
| Indole and indole-related compounds according to the formula (I) or (II) optionally having additional heteroatoms, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. Formula (I), formula (II). R4 being a moiety represented by formula (C4-II-C), R3 being a moiety represented by formula (C3-I or C3-II).
... |
| Pharmaceutical formulation | 20090306113 | 20091210 |
| The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.
... |
| Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase d and rheb | 20090304667 | 20091210 |
| The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibitin mTOR.
... |
| Hydrolases, nucleic acids encoding them and methods for improving paper strength | 20090297495 | 20091203 |
| The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis... |
| Method for producing ice cream | 20090291166 | 20091126 |
| The present invention relates to a method for producing ice cream with a phospholipase.
... |
| Method for producing fractions of a milk composition | 20090285934 | 20091119 |
| The invention relates to a method for producing fractions of a milk composition by treating a milk composition with a phospholipase and separating it into at least two fractions with different fat content. The fractions obtained have improved properties for producing food products. The invention further relates to a method for producing food products from one or more of the fractions obtained. In further aspects the invention relates to methods for producing condensed milk, milk powder, butter and dairy spread from a milk composition treated with a phospholipase
... |
| Isolated peptides having phospholipase inhibitory activity | 20090275083 | 20091105 |
| The invention provides for isolated peptides having phospholipase inhibitory activity, polypeptides comprising phospholipase inhibitory activity and lipases capable of being inhibited by the isolated peptides and/or polypeptides comprising phospholipase inhibitory activity. The invention also relates to nucleic acid constructs, recombinant expression vectors, and recombinant host cells comprising the polynucleotides as well as methods for producing and using the peptides and the polypeptides having lipase inhibitory activity.
... |
| Human phospholipases | 20090274680 | 20091105 |
| The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME.
... |
| Isolated peptides having phospholipase inhibitory activity | 20090275083 | 20091105 |
| The invention provides for isolated peptides having phospholipase inhibitory activity, polypeptides comprising phospholipase inhibitory activity and lipases capable of being inhibited by the isolated peptides and/or polypeptides comprising phospholipase inhibitory activity. The invention also relates to nucleic acid constructs, recombinant expression vectors, and recombinant host cells comprising the polynucleotides as well as methods for producing and using the peptides and the polypeptides having lipase inhibitory activity.
... |
| Human phospholipases | 20090274680 | 20091105 |
| The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME.
... |
| Reagents for the detection of protein phosphorylation in leukemia signaling pathways | 20090263832 | 20091022 |
| The invention discloses nearly 123 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor/scaffold proteins, phosphatase/phospholipases, G proteins/GTPase activating proteins/guanine nucleotide exchange factors, cellular metabolism enzymes, DNA binding proteins, cytoskeletal proteins, cell cycle regulation proteins, proteases, RNA binding proteins, transcription proteins, translation initiation complex proteins, transferases, ubiquitin conjugating system proteins, vesicle proteins, actin binding proteins, apoptosis proteins, chemokine proteins, enzyme proteins extra cellular matrix proteins, helicases, hydrolases, immunoglobin superfamily proteins, inhibitor proteins, isomerases, ligases,... |
| Koji mold-origin phospholipase a2 | 20090263888 | 20091022 |
| It is intended to provide koji mold-origin phospholipase A2 and a DNA encoding it. Namely, phospholipase A2 comprising the following protein (a) or (b): (a) a protein having an amino acid sequence represented by SEQ ID NO: 1 or 2; and (b) a protein having an amino acid sequence derived from an amino acid sequence represented by SEQ ID NO: 1 or 2 by a partial modification and serving as phospholipase A2.
... |
| Reagents for the detection of protein phosphorylation in carcinoma signaling pathways | 20090258442 | 20091015 |
| The invention discloses nearly 474 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Kinase, Adaptor/Scaffold proteins, Phosphatase, G protein Regulator/Guanine Nucleotide Exchange Factors/GTPase Activating Proteins, Cytoskeleton Proteins, DNA Binding Proteins, Phospholipase, Receptor Proteins, Enzymes, DNA Repair/Replication Proteins, Adhesion Proteins, and Proteases, as well as other protein types.
... |
| Phospholipase(s) and use(s) thereof | 20090252718 | 20091008 |
| The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A2, and even more particularly phospholipase A2 derived from the snake venom of Naja sputatrix
... |
| Phospholipase(s) and use(s) thereof | 20090252718 | 20091008 |
| The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A2, and even more particularly phospholipase A2 derived from the snake venom of Naja sputatrix
... |
| Process and formulation for making an egg product with increased functionality and flavor | 20090246319 | 20091001 |
| Treated egg products are provided for imparting the flavor of egg to foods that include egg yolk treated simultaneously with protease and phospholipase. Food flavoring composition are also provided for imparting the flavor egg that can be used in lower amounts than whole egg or egg yolk. Additionally, methods are provided for preparing the egg flavored food compositions. Such egg yolk compositions are prepared by the simultaneous application of phospholipase enzyme and protease enzyme. The method further includes egg flavored food products, such as mayonnaise and salad dressings, which are prepared with the food flavoring composition. The egg flavor compositions can be used in a variety of food products to provide egg flavor and enhanced functionality.
... |
| Azaindole compounds and use thereof as phospholipase-a2 inhibitors | 20090239896 | 20090924 |
| Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. The compounds include azaindoles of the formula below [insert FIG. 6c] in which at least one of CR4, CR5, CR6 and CR7 is replaced by N, and the groups R1-R7 are defined as in claim 1.
... |
| Method for measuring activity of a specific fraction of albumin | 20090230325 | 20090917 |
| Methods of measuring the SFA and sPLA2 activities in a mammalian subject are provided. The methods include: providing a substrate comprising a fluorescently labeled carboxylic acid and a negatively charged phospholipid in an organic solvent such as ethanol, mixing the substrate with phospholipase A2 and a biological sample from the subject, and detecting the fluorescence intensity change to determine the SFA and sPLA2 activity in the sample. A decrease in SFA activity in the test sample as compared to the SFA activity in the control sample indicates that the subject has developed or is about to develop inflammation. An increase in sPLA2 activity in the test sample as compared to the sPLA2 activity in the control sample indicates that the subject has developed or is about... |
| Protein, an antibody and measurement of the protein | 20090233316 | 20090917 |
| A novel mammalian protein related to human hypothetical protein FLJ22662 (SEQ ID NO: 1) and homologous hypothetical proteins from mammal species other than Homo sapiens. The protein is expressed in neutrophils and is characterized as a phospholipase B of a novel family (PLB-II). The protein is characterized in comprising one or two single chain polypeptide SU subunits that are different with respect to their amino acid sequences (i.e. at least one SU1 subunit and/or at least one SU2 subunit), where the amino acid sequence of: i) SU1 comprises SEQ ID NO: 2 or a variant thereof ii) SU2 comprises SEQ ID NO: 3 or a variant thereof. There is also described an antibody preparation which is specifically directed against the mammalian protein and a method for... |
| Method for measuring activity of a specific fraction of albumin | 20090230325 | 20090917 |
| Methods of measuring the SFA and sPLA2 activities in a mammalian subject are provided. The methods include: providing a substrate comprising a fluorescently labeled carboxylic acid and a negatively charged phospholipid in an organic solvent such as ethanol, mixing the substrate with phospholipase A2 and a biological sample from the subject, and detecting the fluorescence intensity change to determine the SFA and sPLA2 activity in the sample. A decrease in SFA activity in the test sample as compared to the SFA activity in the control sample indicates that the subject has developed or is about to develop inflammation. An increase in sPLA2 activity in the test sample as compared to the sPLA2 activity in the control sample indicates that the subject has developed or is about... |
| Protein, an antibody and measurement of the protein | 20090233316 | 20090917 |
| A novel mammalian protein related to human hypothetical protein FLJ22662 (SEQ ID NO: 1) and homologous hypothetical proteins from mammal species other than Homo sapiens. The protein is expressed in neutrophils and is characterized as a phospholipase B of a novel family (PLB-II). The protein is characterized in comprising one or two single chain polypeptide SU subunits that are different with respect to their amino acid sequences (i.e. at least one SU1 subunit and/or at least one SU2 subunit), where the amino acid sequence of: i) SU1 comprises SEQ ID NO: 2 or a variant thereof ii) SU2 comprises SEQ ID NO: 3 or a variant thereof. There is also described an antibody preparation which is specifically directed against the mammalian protein and a method for... |
| Reagents for the detection of protein phosphorylation in leukemia signaling pathways | 20090220991 | 20090903 |
| The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases,... |
| Method for detecting procoagulant phospholipid | 20090221012 | 20090903 |
| The present invention relates to a method for determining the amount of procoagulant phospholipid in a sample, said method comprising steps (i) to (iii) performed in the following order: (i) forming an admixture of the sample and a substrate plasma which has been rendered free or substantially free of procoagulant phospholipid sufficient to at least reduce the capacity of the substrate plasma to coagulate, wherein said substrate plasma has been rendered free or substantially free of procoagulant phospholipid by treatment with a phospholipase; (ii) contacting the admixture with a reagent for activating coagulation of plasma in conditions were procoagulant phospholipids is the rate limiting component of the mixture; and (iii) determining the clotting time if the admixture.
... |
| Broad spectrum antiviral compositions | 20090214510 | 20090827 |
| The instant invention provides compositions and methods for the treatment of viral infections caused by enveloped viruses comprising phospholipase nucleic acid molecules or polypeptides, or fusion molecules comprising phospholipase molecules or functional fragments thereof.
... |
| Broad spectrum antiviral compositions | 20090214510 | 20090827 |
| The instant invention provides compositions and methods for the treatment of viral infections caused by enveloped viruses comprising phospholipase nucleic acid molecules or polypeptides, or fusion molecules comprising phospholipase molecules or functional fragments thereof.
... |
| Phospholipases, nucleic acids encoding them and methods for making and using them | 20080317731 | 20081225 |
| The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP)) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.
... |
| Systemic and intrathecal effects of a novel series of phospholipase a2 inhibitors on hyperalgesia and spinal pge2 release | 20080319065 | 20081225 |
| Phospholipase A2 (PLA2) forins are expressed in spinal cord whose inhibition induces a potent antihyperalgesia. PLA2 inhibitor compounds are provided that include a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four carbon tether. The compounds block Group IVA calcium dependent PLA2 (cPLA2) and/or Group VIA calcium independent PLA2 (iPLA2) and/or Group V secreted PLA2 (sPLA2).
... |
| Process for producing cheese | 20080299252 | 20081204 |
| The present invention relates to a method for producing cheese comprising treating the cheese milk, or a fraction of the cheese milk, with phospholipase C and/or phospholipase D.
... |
| Methods for detection and measurement of secretory phospholipase a2 levels (spla2) in biological fluids | 20080299585 | 20081204 |
| Elevated levels of secretory phospholipase A2 (sPLA2) are associated with a variety of inflammatory conditions, e.g., multiple sclerosis, arteriosclerosis, rheumatoid arthritis, osteoarthritis and sickle cell. ELISA-based assays have been developed for detecting and measuring sPLA2 levels in biological fluids, but these methods are too time-consuming for practical clinical diagnostic use. Disclosed herein in certain embodiments are methods for rapid detection and measurement of sPLA2 levels (e.g., sPLA2 type IIA) in a biological fluid generally, and methods for detection and measurement of sPLA2 levels in urine.
... |
| Medicaments containing enzymes from ciliates for promoting digestion in digestive disorders | 20080292610 | 20081127 |
| A medicament containing enzymes from ciliates selected from the group consisting of hydrolases, lipases, proteases, amylases, glycosidases, phospholipases, phosphodiesterases, phosphatases.
... |
| Diacyl indazole derivatives as lipase and phospholipase inhibitors | 20080287448 | 20081120 |
| Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds as pharmaceutical products.
... |
| Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases | 20080287503 | 20081120 |
| The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.
... |
| Bis-cationic compounds and use thereof | 20080275003 | 20081106 |
| The present invention relates to bis-cationic compounds comprising quaternary ammonium groups and/or quaternary phosphonium groups. The invention also relates to the use of bis-cationic compounds as Phospholipase B inhibitors and the use of bis cationic compounds for the treatment or prevention of microbial infection.
... |
| Process for the preparation and isolation of phosphatides | 20080275006 | 20081106 |
| characterised in that said reaction is carried out in a hydroalcoholic medium containing an aliphatic alcohol and in the presence of bivalent metal oxide.
... |
| Lipase polypeptide | 20080271207 | 20081030 |
| We describe a plant lipase polypeptide and nucleic acids that encode said polypeptide which has homology to a patatin and which has phospholipase and/or triacylglycerol lipase activity.
... |
| Phospholipase c gamma modulation and uses thereof for management of pain and nociception | 20080260718 | 20081023 |
| The present invention provides methods of preventing and treating pain, by modulating, e.g. inhibiting, the activity, function and/or expression of a PLCγ in a subject. The invention further relates to methods of identifying agents capable of modulating the activity and/or expression of a PLCγ, or capable of modulating binding of a ligand or binding partner to a PLCγ, and their use thereof for the prevention and/or treatment of pain. In a further aspect, the invention provides methods for the diagnosis and prognostication of pain by determining whether there is modulation of activity and/or expression of a PLCγ relative to a corresponding control.
... |
| Phospholipase | 20080260903 | 20081023 |
| The present invention is related to a method for producing a phospholipase by processing an expressed fungal peptide and to certain specified phospholipases. Furthermore the invention provides a method for producing cheese with a phospholipase.
... |
| Inositol-phosphate derivatives and method of detecting inositol-1-phosphate | 20080261237 | 20081023 |
| Application: tools allowing the study of the inositol phosphate cycle and therefore, indirectly, the study of seven transmembrane domain receptors coupled to phospholipase C, receptors having a tyrosine kinase activity, and in general enzymes involved in the variations of the intracellular concentration of IP1.
... |
| Specific inhibition of cpla2 enhances the efficacy of radiotherapy | 20080262286 | 20081023 |
| A method for increasing the radiosensitivity of a target tissue in a subject is disclosed. In some embodiments, the methods includes administering a cytosolic phospholipase A2 (cPLA2) antagonist to the subject, whereby the radiosensitivity of the target tissue is increased. Also disclosed are methods for suppressing tumor growth in a subject and methods for inhibiting tumor blood vessel growth.
... |
| Process for producing cheese | 20080220123 | 20080911 |
| The present invention relates to a method for producing cheese comprising treating cheese milk, or a fraction of cheese milk, with a phospholipase and adding whey protein to the cheese milk.
... |
| Production of degummed fatty acid alkyl esters | 20080199924 | 20080821 |
| The present invention relates to a method for producing fatty acid alkyl esters, such as fatty acid methyl esters (FAME) and fatty acid ethyl esters with a low level of impurities such as phospholipids. The method of the invention is simplified by combining two process steps into one single process step and is therefore economically cheaper The method includes mixing water, alcohol, triglyceride and/or free fatty acids a lipolytic enzyme and a phospholipase. Subsequently the aqueous phase, which contains glycerine, residual enzyme and most of the hydrolyzed phospholipids, is separated from the non-aqueous phase, whereby the content of phospholipids in the non-aqueous phase is reduced.
... |
| Method for the high-speed detection and/or measurement of a lipase or phospholipase activity | 20080193958 | 20080814 |
| The invention also relates to the application of the above-mentioned method to the in vitro diagnosis of pathologies linked to an increase in the plasma lipase level.
... |
| Enzymatic degumming utilizing a mixture of pla and plc phospholipases | 20080182322 | 20080731 |
| A method for degumming an oil composition comprises the steps of (a) providing an oil composition containing a quantity of phospholipids, (b) contacting said oil composition simultaneously with one or more phospholipase A enzymes and one or more phospholipase C enzymes, under conditions sufficient for the enzymes to react with the phospholipids to create phospholipid reaction products, and (c) separating the phospholipids reaction products from the oil composition, the remaining oil composition after the separation being a degummed oil composition, whereby during step (b) the reaction of said one or more phospholipase A enzymes proceeds at a faster rate than it would in the absence of said one or more phospholipase C enzymes.
... |
| Agent and compositions comprising the same for inhibiting lipases and phospholipases in body fluids, cells and tissues | 20080182787 | 20080731 |
| The present invention deals with a protein and compositions comprising the same for inhibition of lipases and phospholipases in the body fluids, cells, and tissues for the prevention and treatment of metabolic syndrome, cardiovascular disorders, and inflammatory diseases. The protein is either isolated from plant species or synthesized or produced by recombinant DNA technology.
... |
| Phospholipase c zeta mediated oocyte activation, compositions for use therein, and assays for detecting and identifying agents for treating male infertility | 20080175827 | 20080724 |
| Also, the invention relates to antibodies specific to phospholipase C zeta, preferably human phospholipase C zeta.
... |
| Secreted proteins and uses thereof | 20080176281 | 20080724 |
| The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
... |
| Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors | 20080167339 | 20080710 |
| wherein the substituents are as defined herein. The compounds of formula I wherein R2 is hydrogen are distinguished by favorable effects on disorders of lipid metabolism. They beneficially influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of dyslipidemias and metabolic syndrome and their diverse sequelae such as atherosclerosis, coronary heart disease, heart failure, obesity and diabetes. The compounds of formula I wherein R1 and R2 together form a ring system are distinguished by favorable effects on metabolic disorders. They beneficially influence lipid and sugar metabolism; in particular they lower the triglyceride level and are suitable for the prevention and treatment of type II diabetes and arteriosclerosis and the diverse sequelae thereof.
... |
| Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors | 20080167355 | 20080710 |
| The invention relates to benzooxazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.
... |
| 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | 20080167462 | 20080710 |
| The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved.
... |
| Benzothiazol-2-one derivatives as lipase and phospholipase inhibitors | 20080161370 | 20080703 |
| The invention relates to benzothiazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.
... |
| Anti-inflammatory agent | 20080152734 | 20080626 |
| An anti-inflammatory agent which comprises an oil-soluble licorice extract obtained by extraction treatment of at least either a leguminous plant of the genus Glycyrrhiza or a water extraction residue of a leguminous plant of the genus Glycyrrhiza with an organic solvent, and has at least one effect selected from an inhibitory effect on hyaluronidase activity, an inhibitory effect on hexosaminidase release (i.e., an inhibitory effect on histamine release), an inhibitory effect on platelet aggregation and an inhibitory effect on phospholipase A2 activity.
... |
| Novel calcium-independent phospholipases a2, genes thereof and promoter of the same | 20080154028 | 20080626 |
| Novel calcium-independent phospholipases A2; genes encoding the same; an antibody against them; an inherent promoter or a regulator gene which comprises a base sequence occurring in intron and inducing site-specific expression in response to an external stimulus; a method of expressing a target protein in response to an external stimulus; and an organism having this gene transferred thereinto. Novel calcium-independent phospholipases A2 having an amino acid sequence represented by SEQ ID NO: 1, 3 or 5 or an amino acid sequence derived from such an amino acid sequence by the substitution, deletion or addition of one or more amino acids; a gene having a base sequence occurring in an intron and being capable of initiating RNA transcription due to an external stimulus such as a stimulus... |
| Method for preparation of polyunsaturated fatty acid-containing phosphatidylserine | 20080145902 | 20080619 |
| A method for the preparation of highly polyunsaturated fatty acid-containing phosphatidylserine and phosphatidic acid by phospholipase D-catalyzed transphosphatidylation of fish liver phosphatidylcholine and L-serine is disclosed.
... |
| Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase a2 | 20080139520 | 20080612 |
| Disclosed herein are methods for regulation of fat and/or cholesterol uptake from the gastrointestinal tract and/or regulation of plasma fat and/or cholesterol levels comprising administering to a mammal in need thereof an effective amount of a regulator of pancreatic IB PLA2 functionality. Also disclosed herein are methods of regulating the function of a polypeptide of interest comprising inserting of the 62-66 loop region of a pancreatic IB PLA2 amino acid sequence into the polypeptide of interest; and administering an effective amount of a regulatory molecule that effects its regulation through said amino acid sequence. Further disclosed are novel bile salt compounds that regulate pancreatic IB PLA2. Methods for detecting altered pancreatic IB PLA2 function and methods for identifying an agent suitable for regulating pancreatic IB PLA2... |
| Production of starchy food products | 20080095884 | 20080424 |
| Properties of starchy food products such as noodles, fried products and snack products may be improved by treating the raw materials with a lipolytic enzyme. The enzyme treatment may improve the dough handling during processing the texture, the crispiness, the mouthfeel and the appearance. The enzyme treatment may also reduce the oil content of a fried product increase the firmness and increase the bulkiness (reduce the bulk density) of a fried product. The lipolytic enzyme may have phospholipase, galactolipase and/or triacylglycerol lipase activity.
... |
| Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action | 20070298022 | 20071227 |
| A peptide of phospholipase A2 had been detected in human plasma and synthesised. The peptide was injected into mice and gene expression profiling on many organs performed. Phospholipase A2 showed significant effects on regulation of gene expression in the liver. The genes affected are members of the integrin signalling pathway, wnt pathway and PTEN pathway. The changes in gene expression indicate a positive effect of phospholipase A2 on cell proliferation and invasiveness. The gene annotation points at colorectal cancer.
... |
| Phospholipase inhibitors localized in the gastrointestinal lumen | 20070292385 | 20071220 |
| The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.
... |
| Method for extracting components from a yeast cell culture | 20070292938 | 20071220 |
| The present invention relates to a method for extracting components from yeast cells with a purified phospholipase.
... |
| Modified vp1-capsid protein of parvovirus b19 | 20070286870 | 20071213 |
| The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.
... |
| Methods of detecting lp-pla2 activity | 20070281323 | 20071206 |
| This invention relates to a method for measuring enzymatically active Lipoprotein Phospholipase A2 (Lp-PLA2) in a sample. Further, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample utilizing an enzymatically active Lp-PLA2 standard. In addition, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample containing an enzymatically active Lp-PLA2 standard.
... |
| Frozen foodstuff | 20070259096 | 20071108 |
| Phospholipo-proteins which have been enzyme modified may be used as an emulsifier to improve the emulsion stability of frozen products, e.g., during the freeze thaw and vacuum cool processes. Especially preferred is use of the enzyme phospholipase A to modify egg yolk and to use the modified egg yolk as an emulsifier in frozen products. Creation of a more stable emulsion can be expected to improve the overall appearance of the final product both in the frozen state and after the product has been reheated. Although egg yolk is preferred, examples of other phospholipo-protein containing substances include casein, skim milk, buttermilk, whey, cream, soybean, yeast, whole egg, blood serum and wheat proteins. Egg yolk and/or other sources of phopholipo-protein can be subjected to the action of... |
| Plating media for the presumptive identification of listeria sp, listeria monocytogenes and listeria ivanovii | 20070259393 | 20071108 |
| Isolation plating medium of a first color for the identification of Listeria sp. and Listeria monocytogenes and Listeria ivanovii containing a first chromogenic substrate that responds to phosphatidylinositol-specific phospholipase C enzymes to release precipitate of a second color into the medium and a second chromogenic substrate that responds to beta-glucosidase enzymes to release precipitate of a third color into the medium, and said first, second and third colors contrasting with each other.
... |
| Diagnosis and prognosis of wound infection by measurement of a phospholipase a2 in wound fluid | 20070231380 | 20071004 |
| The present invention relates to the diagnosis, prognosis and/or treatment of wound infection by testing wound fluid for the presence of a marker which is present in an amount which is indicative of infection. The marker may be high molecular weight phospholipase A2 (cPLA2) or a marker which is correlated with cPLA2.
... |
| Genetic markers for predicting disease and treatment outcome | 20070218487 | 20070920 |
| The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy.
... |
| Novel phospholipases and uses thereof | 20070207521 | 20070906 |
| The invention relates to a newly identified polynucleotide sequence comprising a gene that encodes a novel phospholipase isolated from Aspergillus niger. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel phospholipase as well as the amino acid sequence of the full-length functional protein and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein a phospholipase according to the invention is genetically modified to enhance or reduce its activity and/or level of expression.
... |
| Novel lipase | 20070202520 | 20070830 |
| A novel phospholipase A1 (PLA1) having a substrate specificity to phosphatidic acid (PA); a peptide or a polypeptide originating in the above novel PLA1; a polynucleotide encoding the peptide or polypeptide originating in the novel PLA1; a process for producing the peptide or polypeptide originating in the novel PLA1; an antibody against the peptide or polypeptide originating in the novel PLA1; a method of identifying an inhibitor, an antagonist or an activator of the novel PLA1 by using the same; compounds identified by the above method; and medicinal compositions and diagnostic methods by using the same.
... |
| Hydrolases, nucleic acids encoding them and methods for making and using them | 20070202566 | 20070830 |
| The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phosphlipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzyme, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis... |
| Modulators of ion channel trpa1 | 20070196866 | 20070823 |
| This invention provides methods for modulating activities of noxious ion channel TRPAI and methods for screening for novel modulators of TRPAI. Compounds such as bradykinin, eugenol, gingerol, methyl salicylate, allicin, and cinnamaldehyde can be employed to activate cold themosensor TRPAI. These TRPAI agonists can be used in screenings methods to activate TRPA1 and therefore identify novel TRPAI antagonists that can inhibit the activated TRPAI. These TRPAI agonists also provide chemical backbones to synthesize and identify analogs with improved biological or pharmaceutical properties. Further, novel TRPAI modulators can be identified by screening test agents for ability in modulating enzymatic activity or cellular level of phospholipase C.
... |
| Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phosphol | 20070184046 | 20070809 |
| The invention relates to the use of phospholipases, v.gr. sPLA2, as an active agent in the production of pharmaceutical and/or cosmetic compositions for the treatment of diseases caused by micro-organisms, the envelope or membrane of which comprises phospholipids, particularly glycerophospholipids. In particular, said invention relates to the use of sPLA2 from Crotalus durissus terrificus venom as a biocide component for the preparation of compositions for the treatment of viral infections, particularly acquired immunodeficiency states VIH-1 and VIH-2, bacterial and parasitic infections, such as infections caused by plasmodium and leishmania-type parasites.
... |
| Stabilized formulations of phosphatidylserine | 20070160659 | 20070712 |
| Disclosed are stable PS preparations, in powder, liquid and dispersion forms, as well as methods of producing thereof. Most importantly, the stable PS preparations are particularly devoid of residual phospholipase D activity, and the methods of eliminating such activity are also described herein. Lastly, uses of these PS preparations in nutraceuticals or as active agents of pharmaceutical compositions are also provided herein.
... |
| Acidic oil-in-water type emulsion composition | 20070154618 | 20070705 |
| The invention relates to an acidic oil-in-water emulsified composition with a high diglyceride content, which contains fats and oils containing 30 wt % or more diglycerides and enzyme-treated yolk treated with one or more enzymes selected from esterase, lipase and phospholipase, wherein an antioxidant is contained at 1000 to 10000 ppm relative to an oil phase containing the fats and oils and in a weight ratio of 0.4 to 4.5 relative to the net weight of yolk in the enzyme-treated yolk.
... |
| Compositions and methods for identifying modulators of transducisomes, a new class of therapeutic targets | 20070150970 | 20070628 |
| The invention provides cells and methods for identifying modulators of signal transduction, based on transducisome proteins that coordinate and assemble many types of signal transduction proteins. A transducisome is a PDZ domain containing protein that binds at least one signal transduction protein or a PDZ domain containing protein with at least one signal transduction protein bound. Examples of transducisome proteins include INAD, GRIP and other recently identified multi-PDZ domain proteins. Examples of signal transduction proteins include GPCRs, tyrosine kinase receptors, tyrosine phosphatase receptors, ion channels, phospholipases, adenylate cyclases, kinases and G-proteins. Also provided are methods for identifying modulators of signal transduction, proteins (and polynucleotides encoding the same) corresponding to transducisomes, modified transducisomes or defective transducisomes to use in assays of signal transduction, and a screening assay... |
| Method for producing phosholipid | 20070134776 | 20070614 |
| A method for producing a phospholipid using transphosphatidylation, which comprises homogenizing a mixture of a raw material phospholipid, a hydroxyl-containing acceptor, phospholipase D, and water in the absence of an organic solvent to obtain a homogenized mixture; and subjecting the homogenized mixture to a transphosphatidylation reaction at 15° C. to 65° C. The homogenized mixture has a lamellar lyotropic liquid crystal structure. An objective phospholipid can be obtained from the homogenized mixture through transphosphatidylation without using an organic solvent or calcium.
... |
| Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | 20070135383 | 20070614 |
| The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.
... |
| Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors | 20070135385 | 20070614 |
| Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.
... |
| Phospholipase(s) and use(s) thereof | 20070128179 | 20070607 |
| The present invention provides a method for the treatment and/or prevention of a bacterial related condition comprising administering to a subject a therapeutically effective amount of at least one phospholipase, isoform, derivative, mutant and/or fragment thereof. The phospholipase, isoform, derivative, mutant and/or fragment thereof, may be obtained from at least one venom selected from the group consisting of: Daboia russelli russelli, Daboia russelli siamensis, Daboia russelli pulchella, Crotalus adamanteus, Crotalus durissus terrificus, Pseudechis australis, Agkistrodon halys, Pseudechis guttata, Bitis arietans, Bitis gabonica rhinoceros, Echis carinatus, Acanthopis antarticus, Bungarus candidus, Bothrops asper, Bothrops jararacussu and/or Apis mellifera. The present invention also provides isolated peptides comprising at least one amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, an isoform, derivative, mutant... |
| Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase c regulation | 20070111263 | 20070517 |
| The present invention relates to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDIGs of the cells of a] are prepared; c] the hcDIGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDIGs of c] is determined.
... |
| Parathyroid hormone analogues and methods of use | 20070099831 | 20070503 |
| The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose of 2 μg to 60 μg, wherein said PTH peptide analogue has a reduced phospholipase-C activity and maintains adenylate cyclase activity.
... |
| Phospholipase | 20070092945 | 20070426 |
| The present invention is related to a method for producing a phospholipase by processing an expressed fungal peptide and to certain specified phospholipases. Furthermore the invention provides a method for producing cheese with a phospholipase.
... |
| Human phospholipases | 20070082341 | 20070412 |
| The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME.
... |
| Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy | 20070077251 | 20070405 |
| The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds.
... |
| Uses of lp-pla2 in combination to assess coronary risk | 20070077614 | 20070405 |
| This invention relates to a method for assessing risk of Coronary Vascular Disease (CVD). Specifically, it relates to utilizing risk assessment from both Lipoprotein Associated Phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) in combination. In addition the invention relates to a method for assessing risk of Coronary Vascular Disease (CVD) in a patient with low to normal Low Density Lipoprotein Cholesterol (LDL) levels utilizing both LDL and Lipoprotein Associated Phospholipase A2 (Lp-PLA2). Moreover, the invention relates to the use of risk associated with Lp-PLA2, CRP and LDL in combination and specific ranges thereof to predict Coronary Vascular Disease.
... |
| Modulation of epac, phospholipase cepsilon, and phospholipase d to treat pain | 20070060548 | 20070315 |
| The present invention provides methods, compositions, and kits useful for reducing pain in a subject by inhibiting Epac, PLCε, and/or PLD. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that reduce pain. Methods of the invention can involve assaying test agent binding to Epac, PLCε, or PLD. Alternatively, test agents can be screened for their ability to alter the level of Epac, PLCε, or PLD polypeptides, polynucleotides, or action.
... |
| Calcium independent cytosolic phospholipase a2/b enzymes | 20070053897 | 20070308 |
| The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
... |
| Compounds for neutralizing the effects of secreted pla2iia | 20070053912 | 20070308 |
| A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes sPLA2 IIA from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.
... |
| Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer | 20060287346 | 20061221 |
| The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.
... |
| Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors | 20060276522 | 20061207 |
| A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases. (I)
... |
| Glycosyl phosphatidyl inositol specific phospholipase d proteins and uses thereof | 20060269537 | 20061130 |
| Glycosylphosphatidylinositol specific phospholipase D (GPI-PLD) proteins and their medical uses are disclosed, in particular in the treatment and diagnosis of diabetes and complications of diabetes such as insulin resistance, liver dysfunction, disorders involving pancreatectomies and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock. The present invention further relates to variant GPI-PLD polypeptides modified at the phosphorylation site at amino acids 689-692 of the mature human wild-type protein.
... |
| Method for identifying listeria monocytogenes and culture medium | 20060269984 | 20061130 |
| A substrate which can be used for the direct identification of pathogenic bacteria belonging to the genus Listeria by detecting an esterase activity other than Phosphatidyl Inositol-specific Phospholipase C (PI-PLC), an esterase which is specific to the species Listeria monocytogenes. The use of two substrates, one as described above and the other specific for all or some members of the genus Listeria, and a reaction medium containing such a substrate or such a combination of substrates are disclosed. An identification method which exploits such culture media is also disclosed. The invention is particularly applicable in the field of diagnosis.
... |
| Phospholipase variants | 20060251763 | 20061109 |
| The inventors have used protein engineering to develop variants of fungal phospholipases. Starting from a parent phospholipase, they have modified the amino acid sequence to arrive at variants which have phospholipase activity (generally, at roughly the same level as the parent enzyme) and have a lower lipase activity on triglycerides than the parent enzyme.
... |
| Polypeptides having phospholipase b activity and nucleic acids encoding same | 20060252126 | 20061109 |
| The present invention relates to isolated polypeptides having phospholipase B activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.
... |
| Method for detecting procoagulant phospholipid | 20060228765 | 20061012 |
| The present invention relates to a method for determining the amount of procoagulant phospholipid in a sample, said method comprising steps (i) to (iii) performed in the following order: (i) forming an admixture of the sample and a substrate plasma which has been rendered free or substantially free of procoagulant phospholipid sufficient to at least reduce the capacity of the substrate plasma to coagulate, wherein said substrate plasma has been rendered free or substantially free of procoagulant phospholipid by treatment with a phospholipase; (ii) contacting the admixture with a reagent for activating coagulation of plasma in conditions were procoagulant phospholipids is the rate limiting component of the mixture; and (iii) determining the clotting time of the admixture.
... |
| 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors | 20060211755 | 20060921 |
| The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C5-C13alkyl; C,—C,2haloalkyl, C4C,2alkenyl, C4-C12alkynyl, or C,—C5alkylcycloalkyl, C3-C8cycloalkyl, C, C5alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with one to three substituents independently selected from C,—C8a)kyl, C,—C8haloalkyl, ′C2-CBalkenyl, C2-C8a)kynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (C}12)m000C,—Csalkyl, (CH2)mNRaRb, and C,C4alkylcycloalkyl; wherein W and Rb are independently selected from hydrogen, C,CBalkyl, C2-CBalkenyl, C2-CBalkynyl, and C,—C5alkylcycloalkyl; R2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,—C12alkyl, C2C,2haloalkyl, C2-C,2 alkenyl, C2-C12alkynyl, C,—C12alkylaryl, C,—C12alkylcyclohexyl, C, C12alkylcyclopentyl, C,—C12alkylheterocyclic, (CH2)m000H, (CH2)mC0(C,—C,o)alkyl, (CH2)m COO(C,—C,o)alkyl, (CH2)mCOO(C1-C,o)alkylaryl, C,—C,oalkylamino, halo, (CH2)mCONH2, (CH2)rCONRaRb, phenyl, or aryl wherein each of the phenyl or aryl groups is optionally substituted with one to three... |
| Peptide complexes containing phospholipase d | 20060172363 | 20060803 |
| The present invention provides peptide complexes comprising phospholipase D and one or morephospholipase D-interacting peptides. The peptide complexes are useful in screening assays foridentifying compounds effective in modulating the peptide complexes and in treating and/or preventing diseases associated with phospholipase D and it's interacting partners. In addition, methods for screening modulators of the peptide complexes or interacting members thereof are provided.
... |
| 2-substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | 20060173025 | 20060803 |
| The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved.
... |
| Injection of caprine sperm factor (csf), phospholipase c zeta (plczeta) and adenophostin a as alternative methods of activation during nuclear transfer in the caprine species | 20060168671 | 20060727 |
| It has been found that caprine sperm factor, alone or in combination with adenophostin A, produces the Ca2+ oscillations characteristic of egg activation seen with fertilization. The introduction of caprine sperm factor and adenophostin A to eggs to produce reconstructed embryos has been optimized.
... |
| Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions | 20060154252 | 20060713 |
| The present invention relates to a method for identifying therapeutic agents for reducing and monitoring the growth, erosion, rupture or stability of an atherosclerotic plaque comprising the analysis of the differential expression of at least two genes coding proteins chosen among among Stearoyl CoA desaturase, Phosphatidic acid phosphate, and Phosphoinositide-specific-phospholipase-B1, eventually in association with the analysis of the differential expression of at least one gene coding a protein choosen in the group comprising Aldose reductase and aldehyde reductase, Sphingomyelinase, Acid ceramidase, Ceramide glucosyl transferase, Sphingosin phosphate liase, Thymosine beta 4, Aldehyde dehydogenase, ATPase Ca++ binding protein and CD163.
... |
| Agent and compositions comprising the same for inhibiting lipases and phospholipases in body fluids, cells and tissues | 20060147439 | 20060706 |
| The present invention deals with a protein and compositions comprising the same for inhibition of lipases and phospholipases in the body fluids, cells, and tissues for the prevention and treatment of metabolic syndrome, cardiovascular disorders, and inflammatory diseases. The protein is either isolated from plant species or synthesized or produced by recombinant DNA technology.
... |
| Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | 20060142366 | 20060629 |
| The invention relates to novel heteroaryl substituted acetone derivatives which inhibit the enzyme phospholipase A2, pharmaceutical preparations containing these compounds and a method of producing these compounds.
... |
| Inositol phosphate detection assays | 20060115863 | 20060601 |
| Assays for detecting or measuring inositol phosphate, for detecting or measuring signaling pathways, for detecting or measuring the activity of phospholipase C-linked receptors and/or their cognate pathways, for detecting or measuring the activity of inositol kinases and inositol phosphatases, and for screening for compounds that modulate the activity of signaling pathways, receptors and enzymes.
... |
| Phospholipase inhibitors | 20060116409 | 20060601 |
| A novel class of 3-oxo-3H-benzo[d]isoxazole carboxamide compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.
... |
| Tolerogenic vaccine and method | 20060093580 | 20060504 |
| Methods and compositions are provided for treating autoimmune diseases such as diabetes, rheumatoid arthritis, inflammatory bowel disease, and other conditions involving undesired immune responses such as allergies, including food allergies, and graft-versus-host disease. In one embodiment disclosed, regulatory/suppressor T cells are selected or expanded in culture using a phospholipase D (PLD) inhibitor to prevent growth of effector T cells and a growth factor to stimulate the regulatory cells. Antigen-specific regulatory/regulatory T cells can be produced by this method. The regulatory T cells can then be administered to a patient in need of suppressive immunotherapy. In another embodiment, PLD inhibitor, growth factor, and an antigen for which antigen-specific suppressive immunotherapy is desired are administered to a patient via injection, oral or topical administration, or other means known... |
| Frozen food | 20060093724 | 20060504 |
| Phospholipo-proteins which have been enzyme modified may be used as an emulsifier to improve the emulsion stability of frozen products, e.g., during the freeze thaw and vacuum cool processes. Especially preferred is use of the enzyme phospholipase A to modify egg yolk and to use the modified egg yolk as an emulsifier in frozen products. Creation of a more stable emulsion can be expected to improve the overall appearance of the final product both in the frozen state and after the product has been reheated. Although egg yolk is preferred, examples of other phospholipo-protein containing substances include casein, skim milk, buttermilk, whey, cream, soybean, yeast, whole egg, blood serum and wheat proteins.
... |
| Novel therapeutic and prophylactic agents and methods of using the same | 20060078551 | 20060413 |
| A phospholipase A2 inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake, Python reticulatus. The complete PIP polynucleotide sequence was obtained from a cDNA clone encoding PIP, given by SEQ ID NO:1, along with the full amino acid sequence deduced from it. Also disclosed is a recombinant protein PIP, which shows strong lethal toxin neutralizing activity similar to the native PIP, and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases. Also, phospholipase... |
